



For healthcare professionals (HCPs)



Please visit
crineticare.com/hcp or
call **844-276-4357** to
learn more and access
additional resources

David

Living with acromegaly

INDICATION:

PALSONIFY™ (paltusotin) is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS:

- Cholelithiasis and Its Complications:** Cholelithiasis, including related complications such as acute cholecystitis and pancreatitis, have been reported. Monitor patients periodically. Discontinue PALSONIFY if complications of cholelithiasis occur and treat appropriately.

Please see additional Important Safety Information on pages 2-4 and Full Prescribing Information including Patient Information.

CrinetiCARE® offers personalized support to help your eligible patients throughout their treatment journey with PALSONIFY



CrinetiCARE provides access and reimbursement support to help patients start and stay on therapy with PALSONIFY. From navigating insurance coverage to connecting with nurse educators, CrinetiCARE is here to support access for your patients.

- Benefits investigation
- Prior authorization support
- Appeals support

Financial support*

Patient assistance program: Eligible uninsured or underinsured patients may be able to receive PALSONIFY at no cost.

Copay assistance program: Eligible commercially insured patients who are not insured by any federal or government-funded program may pay as little as \$0 for PALSONIFY, with up to \$25,000 in annual support.

Quick start supply*

Patients who experience a delay in their insurance coverage determination can begin therapy while the CrinetiCARE team works on securing insurance coverage.

Nurse educators

Dedicated nurses are available to provide ongoing education; help answer common questions about therapy; and provide consistent, ongoing support throughout your patient's journey with PALSONIFY.

*For more information about CrinetiCARE programs, please call 844-CRN-HELP (844-276-4357).

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS: (cont'd)

- **Hyperglycemia and Hypoglycemia:** Hyperglycemia, diabetes mellitus, or hypoglycemia, may occur. Monitor blood glucose levels when PALSONIFY treatment is initiated or when dosage is altered. Adjust antidiabetic treatment accordingly.
- **Cardiovascular Abnormalities:** Cardiac conduction abnormalities and other ECG changes such as PR interval prolongation, bradycardia, sinus arrest, and atrioventricular block may occur in patients with acromegaly and were reported in PALSONIFY clinical trials. Dosage adjustments of concomitant drugs that have bradycardic effects may be necessary.

Confidence in every step: Enrollment options for CrinetiCARE

Enroll now with our
streamlined form

Enrollment for CrinetiCARE can be completed in 2 ways:



Call CrineticARE at **844-CRN-HELP** (844-276-4357)



Download and complete the PALSONIFY product enrollment form at crineticare.com/hcp

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS: (cont'd)

- **Thyroid Function Abnormalities:** Somatostatin analogs may suppress the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. Periodic assessment of thyroid function is recommended.

Please see additional Important Safety Information on pages 1, 2, and 4 and Full Prescribing Information including Patient Information.

Contact us



844-CRN-HELP
(844-276-4357)



844-CRN-FAXX
(844-276-3299)

Visit us online



Access CrinetiCARE:
crineticare.com/hcp



Access HCP website:
palsonifyhcp.com

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS: (cont'd)

- Steatorrhea and Malabsorption of Dietary Fats:** Somatostatin analog treatment may result in malabsorption of dietary fats and subsequent symptoms of steatorrhea, loose stools, abdominal bloating, and weight loss. If new or worsening symptoms are reported with PALSONIFY, evaluate patients for potential pancreatic exocrine insufficiency and manage accordingly.
- Vitamin B₁₂ Deficiency:** Vitamin B₁₂ deficiency may occur. Monitor vitamin B₁₂ levels, if clinically indicated.

ADVERSE REACTIONS:

Most common adverse reactions (>5%) are diarrhea, abdominal pain, nausea, decreased appetite, sinus bradycardia, hyperglycemia, palpitations, and gastroenteritis.

DRUG INTERACTIONS:

- Strong or Moderate CYP3A4 Inducers: may decrease PALSONIFY exposure. May require an increased dosage of PALSONIFY.
- Proton Pump Inhibitors: may decrease PALSONIFY exposure. May require an increased dosage of PALSONIFY. Avoid concomitant use of proton pump inhibitors in patients who are already on PALSONIFY 60 mg.
- Cyclosporine: may decrease cyclosporine exposure. May require cyclosporine dosage adjustment when used with PALSONIFY; follow therapeutic monitoring recommendations.

**Please report adverse events to Crinetics Pharmaceuticals at 1-833-CRN-INFO
(1-833-276-4636) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.**

Please see Full Prescribing Information including Patient Information.